Skip to main content
OpenTrials
Completed

NCT Number: NCT02902874

Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +

To study the correlation between the polymorphism of the main immunity genes and progression-free survival in ALCL of the child.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

ALCL

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Gustave Roussy

Villejuif, Val De Marne, 94805, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Every patients treated according to COPAD-IGR, HM 89,91 and 97 and ALCL99 protocols and included in related studies
  • Clinical data registered in SFCE database
  • Signed consent form

Exclusion criteria

  • No ALK expression on tumour
  • No consent signed

Treatment and study plan

blood sample

Other

Primary outcomes

  1. Number of single nucleotide polymorphisms in main immunogenicity genes using VERACODE ILLUMINA technology

    Time frame: up to 78 months

Sponsors and collaborators

Lead sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Other

Registry information

Acronym: Immuno ALCL

Important dates

Study start
2010
Primary completion
2020
Study completion
2020
First posted
Sep 16, 2016
Registry last updated
May 27, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.